# US 5,702,948 A · Saccular collagen and compositions and methods for making and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,702,948 A
- Document ID: US5702948A
- Status: Granted
- Kind: A
- Application number: 08/383,744
- Filed: 1995-02-02
- Granted: 1997-12-30
- Earliest claimed: 1995-02-02
- Assignees: The Trustees of the University of Pennsylvania
- Inventors: Mark I. Greene; James G. Davis
- Web page: https://patentgrep.com/patent/US5702948A

## CPC

- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G03C 1/047: Proteins, e.g. gelatine derivatives; Hydrolysis or extraction products of proteins
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G03C: PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES (for photomechanical purposes G03F); PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY (photographic processes characterised by the use or manipulation of apparatus classifiable per se in subclass G03B, see G03B; photomechanical production of textured or patterned surfaces G03F; electrophotography, magnetography G03G)

## Abstract

A substantially purified saccular collagen protein and compositions, including pharmaceutical compositions, that comprise the saccular collagen protein are disclosed. Methods of using the saccular collagen which comprise injecting the saccular collagen into the tissue of an individual are disclosed. Antibodies which bind to the saccular collagen protein, nucleic acid molecules which encode the saccular collagen protein, and oligonucleotides which are identical or complementary to at least a portion of the sequence that encodes the saccular collagen proteins are disclosed. Recombinant expression vector that comprise nucleic acid molecules that encode the saccular collagen protein and host cells, including the cells of transgenic animals, which comprise the recombinant expression vectors are disclosed.

## Claims

### Claim 1

An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the protein having the amino acid sequence of SEQ ID NO:2.

### Claim 2 (depends on 1)

The isolated nucleic acid molecule of claim 1 comprising SEQ ID NO:1.

### Claim 3

A recombinant expression vector comprising a nucleotide sequence that encodes the protein having the amino acid sequence of SEQ ID NO:2.

### Claim 4 (depends on 3)

The recombinant expression vector of claim 3 wherein the vector further comprises a mammary-specific promoter.

### Claim 5 (depends on 3)

The recombinant expression vector of claim 3 wherein the nucleic acid sequence comprises SEQ ID NO:1.

### Claim 6 (depends on 5)

The recombinant expression vector of claim 5 wherein the vector further comprises a mammary-specific promoter.

### Claim 7 (depends on 3)

A host cell comprising the recombinant expression vector of claim 3.

### Claim 8 (depends on 7)

The host cell of claim 7 wherein said host cell comprises a recombinant expression vector that comprises SEQ ID NO:1.

### Claim 9 (depends on 7)

The host cell of claim 7 wherein the host cell is a prokaryotic cell.

### Claim 10 (depends on 7)

The host cell of claim 7 wherein the host cell is a eukaryotic cell.

### Claim 11 (depends on 10)

The eukaryotic host cell of claim 10, wherein the host cell is selected from the group consisting of mammalian cells, insect cells, and yeast cells.

### Claim 12

An isolated oligonucleotide molecule comprising a nucleotide sequence complementary to a nucleotide sequence of at least 50 nucleotides of SEQ ID NO:1.

### Claim 13 (depends on 12)

The oligonucleotide molecule of claim 12 wherein said oligonucleotide molecule is a fragment of SEQ ID NO:1.

### Claim 14 (depends on 12)

The oligonucleotide molecule of claim 12 wherein said oligonucleotide molecule comprises a nucleotide sequence complementary to a nucleotide sequence of at least 100 nucleotides of SEQ ID NO:1.

### Claim 15 (depends on 14)

The oligonucleotide molecule of claim 14 wherein said oligonucleotide molecule is a fragment of SEQ ID NO:1.

### Claim 16

An oligonucleotide molecule comprising a nucleotide sequence complementary to a nucleotide sequence of at least 10 nucleotides of SEQ ID NO:1 between nucleotide 331 and nucleotide 501 of SEQ ID NO:1, or between nucleotide 1600 and nucleotide 1839 of SEQ ID NO:1.

### Claim 17 (depends on 16)

The oligonucleotide molecule of claim 16 wherein said oligonucleotide molecule is a fragment of SEQ ID NO:1.

### Claim 18 (depends on 16)

The oligonucleotide molecule of claim 16 wherein said oligonucleotide molecule comprises a nucleotide sequence complementary to a nucleotide sequence of 15-150 nucleotides of SEQ ID NO:1.

### Claim 19 (depends on 18)

The oligonucleotide molecule of claim 18 wherein said oligonucleotide molecule is a fragment of SEQ ID NO:1.

### Claim 20 (depends on 16)

The oligonucleotide molecule of claim 16 wherein said oligonucleotide molecule comprises a nucleotide sequence complementary to a nucleotide sequence of at least 15-30 nucleotides of SEQ ID NO:1.

### Claim 21 (depends on 20)

The oligonucleotide molecule of claim 20 wherein said oligonucleotide molecule is a fragment of SEQ ID NO:1.

### Claim 22 (depends on 16)

The oligonucleotide molecule of claim 16 wherein said oligonucleotide molecule is a fragment of SEQ ID NO:1 consisting of nucleotides 331-501 of SEQ ID NO:1.

### Claim 23 (depends on 16)

The oligonucleotide molecule of claim 16 wherein said oligonuleotide molecule is a fragment of SEQ ID NO:1 consisting of nucleotides 1600-1839 of SEQ ID NO:1.